Received Apr 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Fever; Diarrhea; Headache; Vomiting; body weakness; chills; This non-serious case was reported by a consumer and described the occurrence of fever in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included acetylsalicylic acid (Several). On 11-APR-2025, the patient received Shingrix. On 12-APR-2025, 1 days after receiving Shingrix, the patient experienced fever (Verbatim: Fever), diarrhea (Verbatim: Diarrhea), headache (Verbatim: Headache), vomiting (Verbatim: Vomiting), weakness generalized (Verbatim: body weakness) and chills (Verbatim: chills). On 18-APR-2025, the outcome of the fever was resolving and the outcome of the diarrhea, headache, vomiting, weakness generalized and chills were resolving (duration 6 days). It was unknown if the reporter considered the fever, diarrhea, headache, vomiting, weakness generalized and chills to be related to Shingrix. It was unknown if the company considered the fever, diarrhea, headache, vomiting, weakness generalized and chills to be related to Shingrix. Additional Information: GSK Receipt Date: 19-APR-2025 The reporter reported that a patient received Shingrix vaccine experienced fever, chills, body weakness, diarrhea, vomiting and headache.
Several